All In Biotech

Drug Trial Radar · NCT01944852

Efficacy and Safety of a Double Icodextrin Dose in Elderly Incident CAPD Patients on Incremental PD.

Efficacy and Safety of a Double Icodextrin Dose in Elderly Incident CAPD Patients on Incremental Peritoneal Dialysis Therapy: the DIDo Study

Last checked: Nov 20, 2026Latest source record: Nov 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 117 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

117

Actual

Start

Mar 2013

Primary completion

Feb 28, 2020

Study completion Feb 28, 2020

Sponsor

Lead sponsor
Pr Eric GoffinAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 18, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The DIDo study is an open-label, randomised, multicentre study with 2 parallel groups in incident CAPD patients aged of 65 at minimum : * One group in which patients will receive 2 bags of icodextrin/day and 1 bag of glucose * One group in which patients will receive 1 bag of icodextrin/day and 2 bags of glucose.

Conditions

  • Renal Insufficiency

Interventions

  • IcodextrinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients stopping 3 bags / dayTime frame: During the treatment phase of 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.